Clinical Trial

A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

Study acronym: ReFocus202
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate if lirafugratinib is efficacious and safe to treat adult patients with previously treated, unresectable, locally advanced or metastatic solid tumors (excluding cholangiocarcinoma) harboring FGFR2 fusion or rearrangement. Participants will: * Take lirafugratinib regularly as instructed by their study doctor. * Visit the clinic as instructed for checkups and tests. * Keep a diary recording each time a dose of lirafugratinib is taken.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-08
Trial Details
NCT Number NCT07359820
Lead Sponsor Elevar Therapeutics
Conditions FGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult
Enrollment 30 participants
Start Date 2026-06-04
Primary Completion 2027-09 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-28